Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer

2018672 citationsJournal Articlegreen Open Access

Authors

Jin‐Young Jang · Seoul National University Hospital

Youngmin Han · Seoul National University Hospital

Hongeun Lee · Seoul National University Hospital

Sun‐Whe Kim · Sungkyunkwan University

Wooil Kwon · Seoul National University Hospital

Kyung-Hun Lee · Seoul National University Hospital

Do‐Youn Oh

Abstract

This is the first prospective randomized controlled trial on the oncological benefits of neoadjuvant treatment in BRPC. Compared to upfront surgery, neoadjuvant chemoradiation provides oncological benefits in patients with BRPC.

Topics & Keywords

Pancreatic and Hepatic Oncology Research Cancer Genomics and Diagnostics Renal cell carcinoma treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Annals of Surgery

Volume 268, Issue 2, pp. 215-222

DOI: 10.1097/sla.0000000000002705

Field-Weighted Citation Impact: 26.66